GSK’s blood cancer drug fails main goal of superiority trial
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
British drugmaker GSK Plc said on Monday its blood cancer drug Blenrep failed the main goal of a late-stage study designed to show that the treatment was better than the standard of care on the market.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2171005642-7096eac42418434eafc1b341520fbe44.jpg "3 Reasons Why Retiring in Texas Might Be Your Best Financial Move")
:max_bytes(150000):strip_icc():format(jpeg)/Clipboard01-ec903bd312d74f6fb9beba1acc310125.png "How the PayPal Mafia Looks Set To Dominate the New Administration")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1365926423-f6ff5bb6d4434e2c9810e1a31bc35a09.jpg "Which U.S. States Have the Highest Grocery Costs and Why")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1178859368-4fa9eb73098c436a9b6ce77b0bb99472.jpg "Death Benefits in a Variable Annuity")